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Prescribed minimum benefits or
minimum prescribed benefits?
To the Editor: Discovery Health notes the contents of Professor
Rayner’s submission to the SAMJ.1
If we had had the opportunity to reply before publication, we
would have been able to confirm that the medication prescribed
for the patient mentioned in the article was approved within our
appeals process on 5 July 2004, before publication of the SAMJ.
We take umbrage that we were not afforded the opportunity to
address and comment on Professor Rayner’s concerns before
publication. It is unfortunate that we have had to write this letter
retrospectively, especially as it may not reach the
readership/audience of the August 2004 journal.
In relation to this article, allow us to clarify further.
1. Discovery Health has always been fully compliant with the
legal requirements of Act 101 and its requirements. In point of
fact, during 2003 Discovery Health was an integral partner in
assisting the Council for Medical Schemes in drafting treatment
algorithms. The regulations permitted the creation of formularies
related to the Chronic Disease List (CDL) conditions, in order that
this benefit could be included in lower premium plans,
promoting affordability and thus allowing more people to access
cover.
2. With specific reference to hypertension, the drug formulary
that we offered was fully compliant with the Council’s guidelines
and requirements and was also in accordance with the most
recent Hypertension Guideline update. The formulary applied to
specific benefit options, and was not a general feature of all
options.
3. Members who purchased an ancillary benefit have access to
an enhanced chronic benefit and are not limited to a formulary.
Those who do have the ancillary benefit qualify for basic chronic
cover as stipulated by the Prescribed Minimum Benefits. The
choice of drugs included within the formulary on these plans
was based on their cost effectiveness, related either to their list
price or to the discount price offered to Discovery Health
members.
For drugs prescribed outside of the formulary, the scheme
allows members to fund their therapy with a monthly medical
allowance set at a similar level to that of items included in the
formulary.
Since legislation has now been implemented with regard to
single exit prices and the discontinuation of mark-ups related to
drugs, Discovery Health can now afford to expand its formulary,
enabling members to access as many drugs as is clinically
appropriate and cost-effective to the Scheme.
As regulations also require consideration of other drugs not
on the formulary for ‘ineffective’ care and for ‘adverse effects’, an
appeal process was created to facilitate this. It is important to
note that this is not an open ‘loophole’ to bypass the formulary,
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Chloroquine-induced retinal toxicity
To the Editor: Dr Rivett’s letter on chloroquine-induced retinal
toxicity1 requires comment.
For Dr Rivett to state that ‘many patients develop profound
visual loss every year as a result of chloroquine toxicity’ is
misleading.  We comment on three aspects: 
1. Data referring to choloroquine alone are scant, as many
authors deal with antimalarials as a group. MacKenzie2 was
probably the first to examine the issue after it became accepted
that retinopathy had been identified as a potential problem. He
quotes data clearly establishing a dose-related effect. Of 928
patients treated with between 2.0 and 3.7 mg/kg/d of
chloroquine ‘for years’, none developed retinopathy. The
incidence of pigmentary degeneration without scotoma or visual
loss increased to 6% at doses above 4.6 mg/kg/d.  At doses
estimated to range from 11 to 33 mg/kg/d, chloroquine is
associated with a sharply rising incidence of scotomas and
decreasing visual acuity. Despite these findings there are widely
quoted figures for visual loss in the literature, ranging from
0.001% to 40%.3 Easterbrook,4 a leading ophthalmologist,
concludes that ‘the incidence of retinopathy is very low at doses
of less than 6.5 mg/kg/day of hydroxychloroqine or less than 3.0
mg/kg/day chloroquine . . .’, and this probably sums up our
current state of knowledge on this subject.  
This matter has received considerable attention in the
dermatology and rheumatology literature, and we would
assume that  most of our colleagues follow the published
guidelines (as published in Dr Rivett’s  letter.)
2. Chloroquine  appears  to be a more effective drug than
hydroxychloroquine.5 Removing the drug from the market and
replacing it with one that is less potent only risks exposing our
patients to potentially more toxic alternatives.                                    
3. While both hydroxychloroquine and chloroquine induce
retinal damage, it is generally accepted that the former is less
toxic. The general opinion is that patients on either drug require
monitoring. The debate at the moment is the most cost effective
manner to achieve this.4
It is unfortunate that the contents of Dr Rivett’s letter were
reported in a local paper,  which could only have generated
anxiety in any patient taking this generally very safe drug. 
Dave Whitelaw
Rheumatology Unit 
Tygerberg Hospital
Tygerberg, W Cape
Sue Jessop
Division of Dermatology
Groote Schuur Hospital
Cape Town
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upon which the premium of the plan was based, but a
mechanism to permit consideration of other costlier drugs, which
become cost-effective because they specifically address a more
serious clinical situation.
Applications for non-formulary drugs for patients with mild
or newly diagnosed conditions not included in this definition
will not be accepted, consistent with good and cost-effective
clinical practice.
E Gottlich 
Principal Clinical Specialist
Discovery Health
1. Rayner B. Prescribed minimum benefits or minimum prescribed benefits? S Afr Med J 2004; 94:
623-624.
Brian Rayner replies: I would like to thank Dr Gottlich,
Principal Clinical Specialist, Discovery Health for replying to my
article in the Journal. It is a very sad state of affairs that I had to
place my viewpoint in the Journal to get his attention. Over the
past year I have made several motivations to Discovery Health
and I have never received a reply. This complete lack of
recognition of my (and other doctors’) professional standing is
certainly cause for umbrage.
It seems that Dr Gottlich has also missed several key points in
my article. Firstly, as I clearly stated, I am in favour of the use of
affordable and cost-effective medication for hypertension. I also
have no issue with the use of formularies by medical funders
provided that these are based on recognised clinical standards,
preferably the Southern African Guidelines for Hypertention.1 I
see many patients who are members of Discovery Health, and I
can usually manage their hypertention effectively with the use of
their formulary. Yet as a prominent specialist in this field I am
referred complicated hypertensive patients, who just cannot be
managed within the confines of a very basic formulary or
algorithm.
Secondly, Dr Gottlich is incorrect in stating that patients on
prescribed minimum benefits (PMBs) are only entitled to receive
benefits within the Council for Medical Schemes algorithm, or
Discovery Health formulary. Apart from the fact that the PMBs
constitute the standard care to be afforded to members on the
lowest options, and should not be construed as to become the
maximum, the regulations to the Medical Schemes Act of 1998
(Act No. 131 of 1998) clearly state that ‘. . . provision must be
made for appropriate exceptions where the protocol has been
ineffective or causes or would cause harm to the beneficiary
without penalty to the beneficiary. Furthermore if managed health
care entails use of a formulary or restricted list of drugs such
formulary or restricted list must be developed on the basis of
evidence-based medicine taking into account considerations of
cost-effectiveness and affordability, but must make provision for
appropriate substitution of drugs where a formulary drug has
been ineffective or causes or would cause harm to the beneficiary
without penalty to the beneficiary.’
Thirdly, despite protestations, Discovery Health’s compliance
with the hypertension algorithm is selective. It does not allow the
use of angiotensin receptor blockers in patients with type 2
diabetes and microalbuminuria.
Fourthly, regarding the specific patient who prompted my
communication, it is simply a distortion of the truth to state that
Discovery Health changed their mind on review. This occurred
because I lodged a formal complaint with the Council for
Medical Schemes. Sadly, most patients are unaware of their rights
in this regard. This leaves medical practitioners with no option
but to face time-consuming administrative hurdles, including
difficulty in accessing clinical peers in such cases as the one I
described.
1. FJ Milne and VJ Pinkney-Atkinson for the Southern African Hypertension Society Hypertension
Guideline Working Groups 2000 and 2003. Hypertension guideline 2003 update.  S Afr Med J
2004; 94: Part 2, 209-226.
A tale of two industries
To the Editor: On 30 September, Merck voluntarily stopped
selling its arthritis drug rofecoxib (Vioxx) because new data
found that it doubled patients’ risk of heart attack and stroke.
Vioxx was a bestseller, with global annual sales of R16 billion.
Merck could have continued marketing the drug with
appropriate health warnings, but it decided that it was in the best
interests of its patients to withdraw the medication.
Cigarettes, too, double the risk of heart attacks and stroke. In
addition, smokers are 10 times more likely to die of emphysema
or lung cancer. In fact, smoking is linked to 50 diseases, from
blindness to foot amputations.
So what have cigarette manufacturers done to protect their
customers? Did they warn of the dangers and prepare to phase
out cigarette sales? Well, no. Actually they did exactly the
opposite. They hid the facts and tried to sell more cigarettes.
The US Justice Department has charged the companies with
behaving like an organised crime syndicate. In a current court
case, US cigarette makers are accused of conspiracy to defraud
consumers by denying the dangers of smoking and passive
smoking; of sponsoring junk science by funding sympathetic
scientists to carry out research to cloud the issue; of manipulating
nicotine levels to keep smokers hooked; of intentionally
marketing to youth; of promoting low-tar cigarettes as less
harmful knowing that this is not true; and of destroying and
concealing documents to hide their illegal activities.
The truth is that the cigarette companies have lost touch with
reality and what is responsible behaviour. British American
Tobacco, for instance, blathers that government proposals for
new picture-based health warnings to better inform the public of
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